AR074398A1 - Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa - Google Patents
Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso paInfo
- Publication number
- AR074398A1 AR074398A1 ARP090104529A ARP090104529A AR074398A1 AR 074398 A1 AR074398 A1 AR 074398A1 AR P090104529 A ARP090104529 A AR P090104529A AR P090104529 A ARP090104529 A AR P090104529A AR 074398 A1 AR074398 A1 AR 074398A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- composition
- fragment
- monoclonal antibody
- anemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpo monoclonal o su fragmento de unión a antígeno que une ferroportina humana 1, que consiste de la secuencia de aminoácido mostrada en SEQ ID NO: 1 y al menos un fragmento de péptido del mismo seleccionado del grupo que consta de SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, y SEQ ID NO: 95 y comprende una LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que comprenden la secuencia de aminoácido mostrada en SEQ ID NOS: 37, 129, 22, 107, 118, y 120, respectivamente. Inhiben la actividad de FPN1 humana y son efectivos en mantener o incrementar el transporte de hierro fuera de células mamíferas y/o mantienen o incrementan el nivel de hierro en suero, conteo de reticulocitos, conteo de glóbulos rojos, hemoglobina, y/o hematocrito en un sujeto in vivo. Polinucleótido que comprende una secuencia de nucleótidos que codifica dicho anticuerpo monoclonal o fragmento de unión a antígeno. Vector de expresión recombinante que comprende dicho polinucleótido. Célula huésped transformada por dicho vector de expresión. Su uso para la preparación de un medicamento útil para el tratamiento o prevención de anemia. Composición farmacéutica que comprende dicho anticuerpo monoclonal o fragmento. Proceso para producir dicho anticuerpo monoclonal o fragmento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074398A1 true AR074398A1 (es) | 2011-01-12 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104529A AR074398A1 (es) | 2008-12-05 | 2009-11-24 | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (es) |
| JP (1) | JP5713917B2 (es) |
| KR (1) | KR101353117B1 (es) |
| CN (1) | CN102238962B (es) |
| AR (1) | AR074398A1 (es) |
| AU (1) | AU2009322587B2 (es) |
| BR (1) | BRPI0922288A2 (es) |
| CA (1) | CA2745618C (es) |
| CY (1) | CY1117355T1 (es) |
| DK (1) | DK2373335T3 (es) |
| EA (1) | EA020472B1 (es) |
| ES (1) | ES2566343T3 (es) |
| HK (1) | HK1158977A1 (es) |
| HR (1) | HRP20160302T1 (es) |
| HU (1) | HUE028585T2 (es) |
| IL (1) | IL212731A0 (es) |
| MX (1) | MX2011005939A (es) |
| NZ (1) | NZ592545A (es) |
| PA (1) | PA8849601A1 (es) |
| PL (1) | PL2373335T3 (es) |
| SG (1) | SG171960A1 (es) |
| SI (1) | SI2373335T1 (es) |
| TW (1) | TW201023891A (es) |
| UA (1) | UA104741C2 (es) |
| WO (1) | WO2010065496A1 (es) |
| ZA (1) | ZA201103941B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014027905A2 (pt) * | 2012-05-14 | 2017-06-27 | Genentech Inc | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) * | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| CA2711826C (en) * | 2008-01-25 | 2018-02-27 | Amgen Inc. | Ferroportin antibodies and methods of use |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en active Application Filing
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active IP Right Cessation
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
- 2011-12-20 HK HK11113719.0A patent/HK1158977A1/zh not_active IP Right Cessation
-
2016
- 2016-03-23 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102238962B (zh) | 2014-02-12 |
| EP2373335B1 (en) | 2016-02-24 |
| CY1117355T1 (el) | 2017-04-26 |
| SI2373335T1 (sl) | 2016-04-29 |
| ES2566343T3 (es) | 2016-04-12 |
| EA020472B1 (ru) | 2014-11-28 |
| EP2373335A1 (en) | 2011-10-12 |
| PA8849601A1 (es) | 2010-07-27 |
| CN102238962A (zh) | 2011-11-09 |
| EA201170764A1 (ru) | 2011-12-30 |
| HRP20160302T1 (hr) | 2016-04-22 |
| CA2745618A1 (en) | 2010-06-10 |
| JP2012510814A (ja) | 2012-05-17 |
| TW201023891A (en) | 2010-07-01 |
| AU2009322587B2 (en) | 2013-09-26 |
| HK1158977A1 (zh) | 2012-07-27 |
| SG171960A1 (en) | 2011-07-28 |
| DK2373335T3 (en) | 2016-05-02 |
| JP5713917B2 (ja) | 2015-05-07 |
| KR101353117B1 (ko) | 2014-02-17 |
| IL212731A0 (en) | 2011-07-31 |
| PL2373335T3 (pl) | 2016-08-31 |
| MX2011005939A (es) | 2011-06-27 |
| NZ592545A (en) | 2012-12-21 |
| HUE028585T2 (en) | 2016-12-28 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| ZA201103941B (en) | 2012-11-28 |
| KR20110084996A (ko) | 2011-07-26 |
| CA2745618C (en) | 2014-06-10 |
| WO2010065496A1 (en) | 2010-06-10 |
| UA104741C2 (uk) | 2014-03-11 |
| AU2009322587A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| JP6865778B2 (ja) | 癌幹細胞を含む癌の診断および治療法 | |
| UA128387C2 (uk) | Антитіло до lag3 | |
| PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| JP2013504589A5 (es) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| CN111201038A (zh) | Psgl-1拮抗剂及其用途 | |
| JP2012100677A5 (es) | ||
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| TW201444866A (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| AR073442A1 (es) | Metodos para tratar cancer y composicion o equipo que comprende un anticuerpo l2g7 humanizado | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| AR084196A1 (es) | Composiciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 | |
| CA2793647A1 (en) | Prophylaxis of colorectal and gastrointestinal cancer | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| AR084627A1 (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica | |
| PH12014501613B1 (en) | Anti-asic1 antibodies and uses thereof | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| IL259036A (en) | asct2-specific binding molecules and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |